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Background/Purpose: The ORBIT I trial evaluated the safety and performance of an orbital atherectomy system
(OAS) in treating de novo calciﬁed coronary lesions. Severely calciﬁed coronary arteries pose ongoing
treatment challenges. Stent placement in calciﬁed lesions can result in stent under expansion, malapposition
and procedural complications. OAS treatment may be recommended to facilitate coronary stent implantation
in these difﬁcult lesions.
Materials/Methods: Fifty patients with de novo calciﬁed coronary lesions were enrolled in the ORBIT I trial.
Patients were treated with the OAS followed by stent placement. Our institution treated 33/50 patients and
continued follow-up for 3 years.
Results: Average age was 54.4 years and 90.9% were males. Mean lesion length was 15.9 mm. The average
number of OAS devices used per patient was 1.3. Procedural success was achieved in 97% of patients.
Angiographic complications were observed in ﬁve patients (two minor dissections, one major dissection and
two perforations). The cumulative major adverse cardiac event (MACE) rate was 6.1% in-hospital, 9.1% at
30 days, 12.1% at 6 months, 15.2% at 2 years, and 18.2% at 3 years. The MACE rate included two in-hospital
non Q-wave myocardial infarctions (MI), one additional non Q-wave MI at 30 days leading to target lesion
revascularization (TLR), and three cardiac deaths.
Conclusions: The ORBIT I trial suggests that OAS treatment may offer an effective method to modify calciﬁed
coronary lesion compliance to facilitate optimal stent placement in these difﬁcult-to-treat patients with
acceptable levels of safety up to 3 years post-index procedure.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0).1. Background and purpose
According to the World Health Organization, people die more from
coronary heart disease than from any other cause. Coronary arterial
disease affects over 68.3 million patients in the United States, making it
the most common form of heart disease [1]. Calciﬁed lesions are
common, with 38% of all lesions showing calciﬁcation as detected byRBIT I trial, 50 patients with de
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Inc. This is an open access article uangiography and 73% of all lesions showing calciﬁcation as detected by
intravascular ultrasound (IVUS) [2]. Current commonly used interven-
tional therapies include atherectomy (debulking), percutaneous trans-
luminal coronary angioplasty (balloon angioplasty) and stenting.
Despite advances in interventional equipment and techniques, the
treatment of calciﬁed coronary lesions continues to pose an ongoing
challenge. Calciﬁed lesions respond poorly to balloon angioplasty, and
are associated with a high frequency of restenosis and target lesion
revascularization (TLR) and pose problems with the use of bare-metal
stents or drug-eluting stents (DES) [3]. Incomplete stent apposition or
expansion and an increased likelihood of stent thrombosis and/or
restenosis may occur [4]. Attempts to remedy incomplete stent
expansion with aggressive high-pressure balloon dilatation may
result in coronary artery rupture [5]. Because of the challenges
associated with the treatment of calciﬁed lesions and the procedural
limitations associated with stenting these lesions, heavy calciﬁcation
has been an exclusion criterion for most stent trials [3,6–9].
As a remedy to this problem, lesion preparation may be
recommended to facilitate coronary stent implantation in these
difﬁcult lesions. The goal of lesion preparation is to facilitate stentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0).
Fig. 1. An eccentrically mounted, diamond-coated crown orbits over an atherectomy guide wire and removes a thin a layer of plaque with each pass of the crown.
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Rotational atherectomy is one of the procedures currently used to
modify calciﬁed plaque and improve overall success of stent
implantation, but distal embolization of debris from the procedure
is a concern. The incidence of slow or no ﬂow in these procedures has
been reported to be 6% to 15% [11,12].
An orbital atherectomy system (OAS), which has been used
successfully to treat peripheral vascular stenosis, has also been
evaluated for the treatment of calciﬁed coronary lesions. The ORBIT
I clinical trial, was conducted to evaluate the safety and long-term
results after OAS treatment of de novo calciﬁed coronary lesions in
adults. The ORBIT I trial was a prospective, non-randomized, multi-
center, feasibility study that evaluated the safety, performance and
effectiveness of the OAS. Initial, 6-month, results have been previously
published [13]. We report on 33 of the patients whowere followed for
3 years at one of the participating centers.
2. Methods and materials
2.1. Trial patients
Patients greater than 18 years of agemeeting the following criteria
were enrolled in the study: 1) target lesion was a de novo coronary
lesion classiﬁed as mild to severely calciﬁed; the target lesion had a
calciﬁed lesion arc in at least 1 quadrant as visualized by IVUS;
2) native coronary artery with a stenosis of ≥50% and b100%
crossable with the atherectomy guide wire; 3) target vessel reference
diameter ≥2.5 mm and ≤4.0 mm by angiogram; 4) main target
vessel classiﬁed as Thrombolysis and Myocardial Infarction (TIMI)
grade 3 ﬂow and 5) lesion length ≤25 mm.
Patients were excluded if there was evidence of an acute
myocardial infarction (MI) within 72 hours prior to the intended
treatment or previous percutaneous coronary intervention (PCI) or
surgery on any vessel within 30 days prior to the intendedFig. 2. The control knob on the control handle allows for positioning the crownwithin the vessel.intervention. Additionally, only one lesion could be treated during the
index procedure. If the patient had two lesions, the patient was staged
and the non-target lesion was treated ﬁrst. Per study protocol, the
creatine kinase-myocardial band (CK-MB) levels were required to be
within laboratory normal ranges at least 12 hours after non-target
lesion treatment andwithin 8 hours prior to treating the target lesion.
2.2. Device description
The Diamondback 360º® Coronary Orbital Atherectomy System
(Cardiovascular Systems, Inc., St. Paul, MN) has been successfully used
to treat calciﬁed peripheral vascular stenosis since 2007. The system
has been adapted for use in coronary arteries. The OAS is a
percutaneous, endovascular system that incorporates the use of
centrifugal force and differential sanding to modify calciﬁed lesions.
The OAS utilizes an eccentrically mounted, diamond-coated crown
(Fig. 1) that orbits over an atherectomy guide wire at high speeds.
Position of the crown within the vessel is controlled via a control
handle (Fig. 2). As treatment proceeds, a thin layer of plaque is
removed with each pass of the crown. This allows the crown to “sand”
away the calciﬁed lesion while the more elastic tissue ﬂexes away
from the crown to increase lumen size andmodify plaque compliance,
depending on the rotational speed chosen. The crown's orbital
diameter expands radially via centrifugal force. The orbital atherec-
tomy procedure removes the calciﬁed stenotic lesion material to
increase vessel compliance prior to balloon angioplasty and stent
placement, which may lead to reduced acute vascular injury.
2.3. Methods
Overall, 50 patients were enrolled in the ORBIT I multi-center
study. One of the participating centers (Care Institute of Medical
Sciences (CIMS), Ahmedabad, India) enrolled and followed 33 of these
50 ORBIT I patients were followed up at Care Institute of Medical
Table 2
Procedural information of patients treated with OAS.
Procedural information Observations
Target vessel, n/N (%)
Left anterior descending 20/33 (60.6)
Left circumﬂex artery 7/33 (21.2)
Right coronary artery 6/33 (18.2)
American College of Cardiology/American Heart Association (ACC/AHA) lesion
class, n/N (%)
Type A 2/33 (6.1)
Type B1 11/33 (33.3)
Type B2 20/33 (60.6)
Mean lesion length (mm) (n = 33), mean ± SD 15.9 ± 4.5
Reference vessel diameter (mm) (n = 33), mean ± SD 3.2 ± 0.4
Mean lumen diameter (mm) (n = 33), mean ± SD 1.3 ± 1.2
Average number of devices (crowns) used (n = 32), mean ± SD 1.3 ± 0.4
Size of devices (crowns) used, n/N (%)
1.25 mm 5/32 (15.6)
1.5 mm 11/32 (34.4)
1.75 mm 18/32 (56.3)
2.0 mm 5/32 (15.6)
Average number stents per lesion (n = 32), mean ± SD 1.1 ± 0.3
Average (range) stent diameter (mm) (n = 35), mean (range) 3.1 (2.5–4.0)
Average (range) stent Length (mm) (n = 35), mean (range) 22 (9–33)
Type of stent, n/N (%)
Cypher 13/35 (37.1)
Endeavor 22/35 (62.9)
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received and Good Clinical Practice (GCP) guidelines were followed
for the conduct of the study. Patients whomet the inclusion/exclusion
criteria and gave written informed consent were enrolled.
All procedures were performed electively. Patients underwent
percutaneous coronary treatment in the standard fashion. Choice of
anticoagulation was at the operators' discretion but activated clotting
time (ACT) was measured to assure appropriate level of antic-
oagulation. Heparin or bivalirudin was given to maintain an
ACT N250 seconds or an ACT of N200 seconds with concomitant use
of glycoprotein IIb/IIIa (GpIIb/IIIa) as per protocol.
The OAS procedure was initiated by crossing the coronary lesion
with the ViperWire Advance® coronary guide wire (Cardiovascular
Systems, Inc., St. Paul, MN). Predilationwith balloon angioplasty could
be performed at the investigators' discretion to allow introduction of
the IVUS imaging catheter for pre-procedural scan completion. The
OAS procedure was initiated with the smallest crown size (choice of
1.25, 1.5, 1.75 or 2.0 mm) that was necessary to modify the calciﬁed
plaque and facilitate the delivery of the stent. OAS rotational crown
speed ranged from 80,000 to 120,000 rotations per minute (rpm).
After OAS treatment, dilatation with balloon angioplasty before and
after stenting was allowed. Post-procedure residual stenosis was
reported as a percentage of the vessel diameter, which was measured
angiographically and evaluated by the treating physician. Device
success was deﬁned as a ﬁnal achievement of ≤50% residual stenosis
of the target lesion after OAS use only (before stent placement or any
other adjunctive treatment), without a device malfunction. Proce-
dural success was deﬁned as ≤20% residual stenosis after stent
placement. Debulking was based on pre- and post-diameter stenosis
of lesions treated with OAS.
Post-stent placement, antiplatelet therapy was given at the
discretion of the investigator and consisted of ≥75 mg of aspirin
given indeﬁnitely and clopidogrel 75 mg daily given according to the
stent manufacturer's recommendation (typically, for 1 year if a DES
stent was implanted). Patients were followed at 30 days, 3 months,
6 months, 2 years and 3 years post-index treatment. The safety of the
OAS was evaluated by procedural success, device success, TLR and
overall major adverse cardiovascular events (MACE) rates at
6 months, 2 years and 3 years. The MACE rate was deﬁned as a
composite endpoint of cardiac death, MI and need for TLR. Per the
study protocol, a Q-waveMI was deﬁned as the development of a new
pathological Q-wave greater than 1 mV in two or more contiguous
leads while a non-Q-wave MI was deﬁned as post-procedure
elevation of CK to 3 times the upper lab normal value with elevated
CK-MB and without pathological Q-waves present on the electrocar-
diogram. TLR was deﬁned as any repeat revascularization of the target
lesion. Reporting of angiographic complications consisted of no ﬂow
or slow ﬂow due to distal embolization, abrupt or threatened closure
of the treated vessel, spasm requiring any surgical intervention
(which could not be resolved via medications), dissection, perforation
and other events seen angiographically.Table 1
Baseline characteristics of enrolled patients.
Baseline characteristic Observations
Average age 54.4 ± 9.1 years
Gender (male), n/N (%) 30/33 (90.9)
Ethnicity (Asian Indian), n/N (%) 33/33 (100)
Angina, n/N (%) 32/33 (97.0)
Stable angina 29/32 (90.6)
Canadian Cardiovascular Society angina class I or II 29/32 (90.6)
Percutaneous coronary intervention history
(N30 days prior to study), n/N (%)
5/33 (15.2)
Coronary bypass graft surgery (prior to study), n/N (%) 1/33 (3.0)Since the study was not designed with a control or powered for
statistical signiﬁcance, the treatment group for analysis was based on
all subjects that consented, met the selection criteria and intended to
be treated with the OAS (intent to treat). All endpoints and data were
reported using descriptive analysis. Where the item was compared to
the baseline, a p-value was calculated.
3. Results
Fifty total patientswere enrolled in themulti-centerORBIT I trial.We
report on results for a subset of 33 patients enrolled at a single center
between May 2008 and July 2008. Predilation with balloon angioplasty
before IVUS was performed in 6/33 patients. Patient baseline charac-
teristics and Procedural information are presented in Tables 1 and 2,
respectively. The 1.75-mm crown was used to treat more than half the
patients and the average number of crowns used per patient was 1.3.
Mean ACT was 274.1 ± 70.5 seconds. All stents implanted were DES.
Stentswere placeddirectly afterOAS in 31of 32patients (96.9%). In only
1 of the 32 patients (3.1%)was balloon angioplasty performed after OAS
treatment and prior to stent placement.
In-hospital, 30-day and 6-month MACE rates are presented in
Table 3. The overall cumulative MACE rate was 6.1% in-hospital (two
non-Q-wave MIs), 9.1% at 30 days (one additional non-Q-wave MI
leading to TLR), 12.1% at 6 months (one event of cardiac death), 15.2%
at 2 years (one additional event of cardiac death [two total cardiac
deaths]) and 18.2% at 3 years (one additional event of cardiac death
[three total cardiac deaths]). There was no Q-wave MI.Table 3
Cumulative MACE rates.
In-
hospital
30-day
follow-up
6-month
follow-up
2-year
follow-up
3-year
follow-up
Cardiac
death
0 0 3% (1/33) 6.1% (2/33) 9.1% (3/33)
Q-wave MI 0 0 0 0 0
Non-Q-wave
MI
6.1% (2/33) 6.1% (2/33) 6.1% (2/33) 6.1% (2/33) 6.1% (2/33)
TLR 0 3% (1/33) 3% (1/33) 3% (1/33) 3% (1/33)
MACE rate 6.1% (2/33) 9.1% (3/33) 12.1% (4/33) 15.2% (5/33) 18.2% (6/33)
Table 4
Change in vessel diameter.
% Diameter stenosis,
mean ± SD
Pre OAS (n = 33) 85.6 ± 7.8
Post OAS (n = 32) 39.4 ± 10.1
Change (Debulking) (n = 32) 45.9 ± 11.8⁎
Post Stent (n = 32) 0.3 ± 1.8
⁎ p b 0.0001.
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minor dissections, one major dissection and two perforations). The
investigators classiﬁed the three dissections as types A to C without
clinical sequelae. After stent placement two perforations were
reported; however, one was reclassiﬁed as a type C dissection
according to the National Heart, Lung and Blood Institute (NHLBI)
classiﬁcation system for coronary artery dissection type [14], since it
spontaneously resolved, as non-ﬂow limiting and non-consequential
after stent placement. The reported second perforation was managed
by balloon inﬂation alone and echocardiography conﬁrmed the
absence of pericardial effusion. This lesion had been treated with a
1.75-mm crown and a 2.5 × 14-mm stent. There was no occurrence of
no ﬂow/slow ﬂow due to distal embolization.
Procedural success (≤20% residual stenosis after stent placement)
was achieved in 97% (32/33) of patients. Mean diameter stenosis was
85.6% pre-OAS, 39.4% post-OAS and 0.3% post-stent placement based
on investigator-reported outcome. Device success was 100% (32/32)
(b50% residual stenosis after OAS use only with no device malfunc-
tion). In one subject, the IVUS catheter could not cross the lesion so
OAS treatment was not performed. Since the patient was intended to
treat, the patient was included in follow-up. All stents were
successfully deployed. Change in vessel diameter is shown in
Table 4. The pre- to post-atherectomy difference in mean diameter
stenosis was statistically signiﬁcant (p b 0.0001).
4. Discussion
Simple atherosclerotic lesions are treated using balloon angioplas-
ty, with or without stents, with a high degree of success. More
complex atherosclerotic plaques containing calcium present addi-
tional challenges for interventional procedures. The deposition of
calcium within these lesions reduces vessel elasticity and may create
eccentric expansion during balloon angioplasty. This typically leads to
increased perforation and/or dissection rates in this population [15].
Rotational atherectomy has been employed to treat patients with
coronary arterial calciﬁc disease by enlarging the vessel lumen. The
mechanism of action, which uses a rotating, diamond-coated burr
within the vessel has been shown to have potential utility to prepare
calciﬁed lesions for further treatment that will be used to prevent
restenosis (e.g., stent) [5]. A recent study by Brogan et al. [16]
highlighted the beneﬁts of debulking when treating patients with
calciﬁed coronary arteries. Using quantitative angiographic methods,
they demonstrated the beneﬁcial effects of calcium plaque reduction
using rotational atherectomy. These beneﬁts include increase in acute
luminal gain, decreased vessel stretch and less elastic recoil resulting
in procedural success in 37 of 41 patients (90%). Moussa et al. [17]
treated 75 consecutive patients (106 lesions) with rotational
atherectomy prior to coronary stenting and reported procedural
success in 93.4% of lesions. In spite of these successes, other reports
suggest that distal embolization of atherectomy fragments may result
in no-reﬂow or slow ﬂow, which can result in serious complications
such as adverse ischemic and clinical events including but not limited
to microvascular spasm, MI and no-reﬂow [18].
The OAS has additional advantages over other atherectomy devices.
The average particle size created by rotational atherectomy is 5–10 μm
[19] vs. particles averaging less than 2 μm when the OAS is used [20].Particles ablated from the occluding plaque by the OAS are removed
through the reticuloendothelial system. In addition, the orbit of the OAS
crown can be regulated via the crown's rotational speed, to achieve
optimal plaquemodiﬁcation. This ability to treat the lesionwith a single
device may allow for signiﬁcant cost savings to be realized.
Perforation rates of 0 to 1.5% have been reported with high-speed
rotational atherectomy and differ based on technique [19]. In this
single-center subset of ORBIT I trial patients, two minor dissections,
one major dissection and two perforations occurred. Use of smaller
crown sizes and improved technique is expected to reduce acute
complications in the future. In comparison, the OAS used in this study
did not cause slow ﬂow or distal embolization. This may be due to the
mechanism of action. The elliptical orbit allows blood and micro-
debris to ﬂow past the crown, thus continually dispersing the
particulate, cooling the crown and reducing the risk of thermal injury
to the target vessel. In comparison, rotational atherectomy utilizes a
concentric burr that does not allow blood and micro-debris to ﬂow
past the burr.
Cumulative MACE rate was 15.2% at 24-month and 18.2 % at
36-month follow-ups. Historically, when balloon angioplasty and
stents are used to treat these lesions there have been MACE rates
ranging from 11% to 15.8% at 15 months [4]. It is difﬁcult to compare
the MACE rates in the ORBIT I trial, since it was a small, non-
consecutive study. However, the results are less than the MACE rates
reported in the few DES trials that have included moderate and
severely calciﬁed lesion [21,22]. As described above, one of the
limitations in stent trials is that patients with calciﬁed lesions were
excluded while the ORBIT I trial speciﬁcally studied patients with
calciﬁed coronary arteries. The treatment associated with these
challenging calciﬁed lesions often leads to increased MACE rates. As
demonstrated by the ROTAXUS study, the MACE rate for calciﬁed
lesions treated with rotational atherectomy and DES was approx-
imately 24% at 9 months [23]. In contrast, the ORBIT I trial
demonstrated that patients with calciﬁed coronary artery lesions
treated with OAS and stent placement had a reduction in diameter
stenosis and lower rate of MACE rates (9.1% at 30 days, 12.1% at
6 months, 15.2% at 2 years and 18.2% at 3 years).
5. Conclusion
The ORBIT I trial, a clinical pilot study, suggests that the OAS
treatment may offer effective method to modify calciﬁed coronary
lesion compliance to facilitate optimal stent placement in these
difﬁcult-to-treat patients. Patient treatmentwith the OAS resulted in a
low cumulative MACE rate acutely and at 6, 12, 24 and 36-month
follow-up time points. Future improvements in crown selection and
operation technique should reduce acute complications that were
observed in this ﬁrst human feasibility study. A larger multi-center,
pivotal trial has been completed in the United States to evaluate OAS
safety and efﬁcacy in a larger patient population.
6. Study limitations
This trial has several limitations. The trial was designed as a
feasibility study and, therefore, lacked a control group for comparison.
Additional limitations of ORBIT I trial subset, are the small number of
patients (33) treatedwith OAS at a single center. Core lab adjudication
was lacking in this pilot study. The study protocol called for percent
diameter stenosis to be calculated by IVUS during the index
procedure. However, due to multiple difﬁculties experienced during
pullback of the IVUS catheters, the IVUS core lab could not assess
plaque volume and percent diameter stenosis for all 33 patients. These
difﬁculties were due primarily to long lesion length and calciﬁcation,
which contributed to the inability to insert the IVUS catheters and
automate pullback. Therefore, plaque volume and percent diameter
stenosis could not be calculated. As with any new technology, a
208 P. Bhatt et al. / Cardiovascular Revascularization Medicine 15 (2014) 204–208learning curve is present. Additional experience may reduce the
incidence of intraprocedural complications. A larger study is required
to demonstrate safety.
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